Evercore ISI raised the firm’s price target on Crispr Therapeutics (CRSP) to $74 from $62 and keeps an Outperform rating on the shares. The updated target reflects strong momentum as Vertex Pharmaceuticals’ (VRTX) new guidance for Casgevy “looks promising,” says the analyst, who adds that the setup for Crispr “appears even better than initially appreciated.”